Compare Ascendis Pharma A/S (ASND) vs Bank of New York Mellon Corp (BNY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Bank of New York Mellon Corp — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Bank of New York Mellon Corp trades at $151.63 (market cap $104.27B). The key difference: Bank of New York Mellon Corp is far larger — about 5.9× Ascendis Pharma A/S's market cap, and Bank of New York Mellon Corp pays a 1.4% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | BNY | |
|---|---|---|
Market Cap | $17.74B | $104.27B |
Sector | Health | Financials |
52-Week High | $277.18 | $152.91 |
52-Week Low | $163.32 | $93.72 |
Enterprise Value | $18.11B | — |
Dividend Yield | — | 1.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
BNY trades at $151.92, down 0.22% today, with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The stock shows robust fundamentals with a 29.21% net income margin and 14.81% ROE, supported by a 19% dividend increase announcement in June 2026. Analyst consensus is mixed with 38.1% buy ratings and a $156 price target, slightly above current levels.
Outlook remains positive given consistent earnings beats and digital asset expansion, but risks include high RSI levels suggesting overbought conditions and sensitivity to interest rate changes. The stock offers steady income growth with dividend hikes, yet investors should monitor execution on large investing outflows and competitive pressures in custody banking.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Bank of New York Mellon Corp
BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with about $41.1 trillion in under custody and administration (as of Dec. 31, 2020), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.2 trillion in assets.
Read more on BNY →
